MK-6482 to Treat Renal Cell Carcinoma in Von Hippel-Lindau Disease Patients
Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, discusses data presented on MK-6482 for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
Von Hippel-Lindau disease is a genetic disease characterized by the formation of tumors and cysts in many different parts of the body. The condition can result in a variety of noncancerous or cancerous tumors due to mutations in the VHL gene. People with von Hippel-Lindau disease are also at increased risk for developing other cancers, including renal cell carcinoma.
MK-6482 is an HIF-2α Inhibitor being investigated in a non-randomized phase 2 clinical trial to treat people with von Hippel-Lindau disease-associated renal cell carcinoma.
The primary endpoint of the study was the objective response rate in kidney masses. This study observed that 36% of patients who had confirmed responses with an additional 11% of patients having unconfirmed, partial responses. Furthermore, there were objective responses seen in some patients’ pancreatic lesions as well as stabilization or improvement in patients’ hemangioblastomas.
MK-6482 was recently given breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). As Dr. Jonasch says, the psychological burden of von Hippel-Lindau disease on patients is tremendous and he hopes that this designation will lead to approval of MK-6482 in the next few years.
For more information about Von Hippel-Lindau disease and other rare cancers, visit checkrare.com/diseases/cancers/
-
Category
No comments found